SINGULAR GENOMICS SYSTEMS IN (OMIC)
US82933R3084 - Common Stock
Taking everything into account, OMIC scores 2 out of 10 in our fundamental rating. OMIC was compared to 55 industry peers in the Life Sciences Tools & Services industry. OMIC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. OMIC is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
OMIC had negative earnings in the past year.
In the past year OMIC has reported a negative cash flow from operations.
OMIC had negative earnings in each of the past 5 years.
In the past 5 years OMIC always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -41.77%, OMIC is doing worse than 81.82% of the companies in the same industry.
OMIC's Return On Equity of -66.73% is on the low side compared to the rest of the industry. OMIC is outperformed by 76.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.77% | ||
| ROE | -66.73% | ||
| ROIC | N/A |
ROA(3y)-30.4%
ROA(5y)-41.68%
ROE(3y)-39.09%
ROE(5y)-60.75%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
OMIC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
OMIC does not have a ROIC to compare to the WACC, probably because it is not profitable.
OMIC has less shares outstanding than it did 1 year ago.
Compared to 1 year ago, OMIC has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -2.81, we must say that OMIC is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.81, OMIC is doing worse than 87.27% of the companies in the same industry.
OMIC has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
OMIC has a better Debt to Equity ratio (0.05) than 65.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.81 |
ROIC/WACCN/A
WACC11.55%
2.3 Liquidity
A Current Ratio of 8.77 indicates that OMIC has no problem at all paying its short term obligations.
OMIC has a Current ratio of 8.77. This is amongst the best in the industry. OMIC outperforms 85.45% of its industry peers.
A Quick Ratio of 8.04 indicates that OMIC has no problem at all paying its short term obligations.
OMIC has a Quick ratio of 8.04. This is amongst the best in the industry. OMIC outperforms 85.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.77 | ||
| Quick Ratio | 8.04 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 3.41% over the past year.
The Revenue has grown by 27.10% in the past year. This is a very strong growth!
EPS 1Y (TTM)3.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.38%
Revenue 1Y (TTM)27.1%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%45.94%
3.2 Future
Based on estimates for the next years, OMIC will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.60% on average per year.
Based on estimates for the next years, OMIC will show a very strong growth in Revenue. The Revenue will grow by 108.16% on average per year.
EPS Next Y9.67%
EPS Next 2Y8.48%
EPS Next 3Y9.6%
EPS Next 5YN/A
Revenue Next Year20.37%
Revenue Next 2Y96.92%
Revenue Next 3Y108.16%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for OMIC. In the last year negative earnings were reported.
Also next year OMIC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.48%
EPS Next 3Y9.6%
5. Dividend
5.1 Amount
OMIC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SINGULAR GENOMICS SYSTEMS IN
NASDAQ:OMIC (11/21/2024, 8:00:02 PM)
21.9
+0.22 (+1.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap54.75M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.77% | ||
| ROE | -66.73% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 8.77 | ||
| Quick Ratio | 8.04 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)3.41%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y9.67%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)27.1%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y